Scinovex
article Open AccessTop 10% cited

A Phase I and Pharmacological Study with Imidazolium-<b> <i>trans-</i> </b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

Clinical Cancer Research · 2004 · Vol. 10(11) · pp. 3717–3727
Jeany M. Rademaker-LakhaiH.J.G.D. van den BongardDick PluimJos H. BeijnenJan H.M. Schellens

Abstract

NAMI-A can be administered safely as a 3-h i.v. infusion at a dose of 300 mg/m(2)/day for 5 days, every 3 weeks.

Radiopharmaceutical Chemistry and ApplicationsMetal complexes synthesis and propertiesLung Cancer Treatments and MutationsPharmacokineticsRutheniumPharmacologyToxicityMedicineLimitingAdverse effectChemistryInternal medicineBiochemistry

MeSH terms

AdultAgedAntineoplastic AgentsDimethyl SulfoxideDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedModels, ChemicalOrganometallic CompoundsRutheniumTime FactorsTreatment OutcomeRuthenium Compounds
Citations
820
FWCI
11.96
field-weighted impact
References
33
Percentile
99%
vs. same field & year
Citations per year
References
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.